Connecticut Senate Bill 191, which would expand the state’s existing psychedelics pilot program, passed the House with a 122-27 vote and the Senate with a 35-0 vote, and has now headed to Governor Ned Lamont.

Originally enacted in 2023, the pilot program currently gives veterans, retired first responders, and direct care healthcare workers access to MDMA-assisted and psilocybin-assisted therapy programs as part of research programs approved by the FDA. The program does not list specific medical conditions, allowing for flexibility based on FDA-approved research programs.

This new bill would allow any adults aged 18 or older to take part in these programs, assuming they meet clinical eligibility criteria established by the institutional review board of the medical school selected to administer the programs.

Additionally, the new bill would allow the pilot program to continue to exist even if the FDA approves an MDMA or psilocybin drug for medical use.

If enacted, the bill would go into effect July 1, 2026.